Challenging cases encountered in colorectal cancer screening for Lynch syndrome reveal novel findings: Nucleolar MSH6 staining and impact of prior chemoradiation therapy

Human Pathology

Volumn 42, Issue 9, 2011, Pages 1247-1258

  Radu, Oana M ^a   Nikiforova, Marina N ^a   Farkas, Linda M ^a   Krasinskas, Alyssa M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Chemoradiation therapy; Lynch syndrome; Microsatellite instability; Mismatch repair proteins; MSH6

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; MISMATCH REPAIR PROTEIN; OXALIPLATIN; PROTEIN MSH6;

ADULT; AGED; ARTICLE; CANCER SCREENING; CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE INSTABILITY; NUCLEOLUS; POLYMERASE CHAIN REACTION; PROTEIN DEPLETION; REAL TIME POLYMERASE CHAIN REACTION; THERAPY EFFECT;

ADENOSINE TRIPHOSPHATASES; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL NUCLEOLUS; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; RADIOTHERAPY; RETROSPECTIVE STUDIES;

EID: 80051679968     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.11.016     Document Type: Article

References (38)

1. Hampel H., Frankel W.L., and Martin E. Feasibility of screening for Lynch syndrome among patients with colorectal cancer J Clin Oncol 26 2008 5783 5788
2. Hampel H., Frankel W.L., and Martin E. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer) N Engl J Med 352 2005 1851 1860
3. Vasen H.F., Mecklin J.P., Khan P.M., and Lynch H.T. The International Collaborative Group on HNPCC Anticancer Res 14 1994 1661 1664 (Pubitemid 24357002)
4. Laghi L., Bianchi P., Roncalli M., and Malesci A. Re: Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability J Natl Cancer Inst 96 2004 1402 1403 author reply 3-4
5. Umar A., Boland C.R., and Terdiman J.P. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability J Natl Cancer Inst 96 2004 261 268 (Pubitemid 38256271)
6. Julie C., Tresallet C., and Brouquet A. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening Am J Gastroenterol 103 2008 2825 2835 quiz 36
7. Bianchi F., Galizia E., and Catalani R. CAT25 is a mononucleotide marker to identify HNPCC patients J Mol Diagn 11 2009 248 252
8. Thorland E.C., and Thibodeau S.N. Hereditary nonpolyposis colorectal cancer DGB Leonard, Molecular Pathology for Clinical Practice 2007 Springer 223 232
9. Nikiforov Y.E., Steward D.L., and Robinson-Smith T.M. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules J Clin Endocrinol Metab 94 2009 2092 2098
10. Berg A.O. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives Genet Med 11 2009 35 41
11. Shia J., Tang L.H., and Vakiani E. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel Am J Surg Pathol 33 2009 1639 1645
12. Hall G., Clarkson A., and Shi A. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma Pathology 42 2010 409 413
13. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry J Mol Diagn 10 2008 293 300 (Pubitemid 352019113)
14. Shia J., Ellis N.A., and Klimstra D.S. The utility of immunohistochemical detection of DNA mismatch repair gene proteins Virchows Arch 445 2004 431 441 (Pubitemid 39592745)
15. Klarskov L., Ladelund S., and Holck S. Interobserver variability in the evaluation of mismatch repair protein immunostaining Hum Pathol 2010
16. Overbeek L.I., Ligtenberg M.J., and Willems R.W. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting Am J Surg Pathol 32 2008 1246 1251
17. Barrow E., Jagger E., and Brierley J. Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome Histopathology 56 2010 331 344
18. Mangold E., Pagenstecher C., and Friedl W. Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining J Pathol 207 2005 385 395 (Pubitemid 43025686)
19. Southey M.C., Jenkins M.A., and Mead L. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer J Clin Oncol 23 2005 6524 6532 (Pubitemid 46190244)
20. Shia J., Klimstra D.S., and Nafa K. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms Am J Surg Pathol 29 2005 96 104 (Pubitemid 40023956)
21. Halvarsson B., Lindblom A., Rambech E., Lagerstedt K., and Nilbert M. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer Fam Cancer 5 2006 353 358 (Pubitemid 44924111)
22. Bellizzi A.M., Crowder C.D., Marsh W.L., Hampel H., and Frankel W.L. Mismatch repair status in a cohort of rectal adenocarcinomas before and after chemoradiation Mod Pathol 23 2010 137A
23. Guo M., Klimstra D., and Tang L. Immunohistochemistry (IHC) for DNA mismatch repair (MMR) proteins in colorectal carcinoma: what does scanty staining for MSH6 mean? Mod Pathol 23 2010 433A
24. Bao F., Rennert N., and Yantiss R.K. Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma Mod Pathol 23 2010 136A
25. Thibodeau S.N., Bren G., and Schaid D. Microsatellite instability in cancer of the proximal colon Science 260 1993 816 819 (Pubitemid 23167612)
26. Barnetson R.A., Tenesa A., and Farrington S.M. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer N Engl J Med 354 2006 2751 2763 (Pubitemid 43974193)
27. Wahlberg S.S., Schmeits J., and Thomas G. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families Cancer Res 62 2002 3485 3492 (Pubitemid 34651396)
28. Ward R., Meldrum C., and Williams R. Impact of microsatellite testing and mismatch repair protein expression on the clinical interpretation of genetic testing in hereditary non-polyposis colorectal cancer J Cancer Res Clin Oncol 128 2002 403 411 (Pubitemid 35007550)
29. Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing J Mol Diagn 10 2008 301 307 (Pubitemid 352019114)
30. Suraweera N., Duval A., and Reperant M. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR Gastroenterology 123 2002 1804 1811 (Pubitemid 35408304)
31. Berends M.J., Wu Y., Sijmons R.H., and Mensink R.G. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant Am J Hum Genet 70 2002 26 37 (Pubitemid 34031695)
32. Hendriks Y.M., Wagner A., and Morreau H. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance Gastroenterology 127 2004 17 25 (Pubitemid 38962270)
33. V. Deschoolmeester, Baay M., and Wuyts W. Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers J Mol Diagn 10 2008 154 159 (Pubitemid 351436269)
34. Ferreira A.M., Westers H., and Sousa S. Mononucleotide precedes dinucleotide repeat instability during colorectal tumour development in Lynch syndrome patients J Pathol 219 2009 96 102
35. Loukola A., Eklin K., and Laiho P. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC) Cancer Res 61 2001 4545 4549 (Pubitemid 32685787)
36. Fonseca F.L., Sant Ana A.V., and Bendit I. Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients Breast Cancer Res 7 2005 R28 R32
37. Watanabe Y., Koi M., Hemmi H., Hoshai H., and Noda K. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer Br J Cancer 85 2001 1064 1069 (Pubitemid 33016010)
38. Choi M.Y., Lauwers G.Y., Hur C., Willett C.G., and Chung D.C. Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation Int J Radiat Oncol Biol Phys 68 2007 1584 (Pubitemid 47176835)